[
  {
    "ts": null,
    "headline": "Incyte Corp. stock outperforms competitors on strong trading day",
    "summary": "Incyte Corp. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=b8adc92e0ba86f98c005ef04c8f81b7967dc786249d6b6313b5150434aab184e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760461920,
      "headline": "Incyte Corp. stock outperforms competitors on strong trading day",
      "id": 137153472,
      "image": "",
      "related": "INCY",
      "source": "MarketWatch",
      "summary": "Incyte Corp. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=b8adc92e0ba86f98c005ef04c8f81b7967dc786249d6b6313b5150434aab184e"
    }
  },
  {
    "ts": null,
    "headline": "How ESMO Congress Spotlight on Early Cancer Drugs Could Influence Incyte’s (INCY) Investment Outlook",
    "summary": "Incyte recently announced that its Phase 1 proof-of-concept studies for INCA33890 and INCB161734 will be featured as oral presentations at the 2025 European Society for Medical Oncology Congress, focusing on potential treatments for advanced solid tumors such as colorectal cancer and pancreatic ductal adenocarcinoma. This recognition emphasizes both the early-stage promise of Incyte’s investigative drugs and the scientific community’s interest in novel approaches to difficult-to-treat...",
    "url": "https://finnhub.io/api/news?id=65868835711f3be547934add00e256f9d5f75373ab457d9bdbff3a221d467a0c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760451017,
      "headline": "How ESMO Congress Spotlight on Early Cancer Drugs Could Influence Incyte’s (INCY) Investment Outlook",
      "id": 137086535,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte recently announced that its Phase 1 proof-of-concept studies for INCA33890 and INCB161734 will be featured as oral presentations at the 2025 European Society for Medical Oncology Congress, focusing on potential treatments for advanced solid tumors such as colorectal cancer and pancreatic ductal adenocarcinoma. This recognition emphasizes both the early-stage promise of Incyte’s investigative drugs and the scientific community’s interest in novel approaches to difficult-to-treat...",
      "url": "https://finnhub.io/api/news?id=65868835711f3be547934add00e256f9d5f75373ab457d9bdbff3a221d467a0c"
    }
  }
]